Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Syk-dependent glycolytic reprogramming in dendritic cells regulates IL-1β production to β-glucan ligands in a TLR-independent manner.

Thwe PM, Fritz DI, Snyder JP, Smith PR, Curtis KD, O'Donnell A, Galasso NA, Sepaniac LA, Adamik BJ, Hoyt LR, Rodriguez PD, Hogan TC, Schmidt AF, Poynter ME, Amiel E.

J Leukoc Biol. 2019 Dec;106(6):1325-1335. doi: 10.1002/JLB.3A0819-207RR. Epub 2019 Sep 11.

PMID:
31509298
2.

Regulation of Dendritic Cell Immune Function and Metabolism by Cellular Nutrient Sensor Mammalian Target of Rapamycin (mTOR).

Snyder JP, Amiel E.

Front Immunol. 2019 Jan 14;9:3145. doi: 10.3389/fimmu.2018.03145. eCollection 2018. Review.

3.

Tetrahydroisoquinoline CXCR4 Antagonists Adopt a Hybrid Binding Mode within the Peptide Subpocket of the CXCR4 Receptor.

Katzman BM, Cox BD, Prosser AR, Alcaraz AA, Murat B, Héroux M, Tebben A, Zhang Y, Schroeder GM, Snyder JP, Wilson LJ, Liotta DC.

ACS Med Chem Lett. 2018 Nov 30;10(1):67-73. doi: 10.1021/acsmedchemlett.8b00441. eCollection 2019 Jan 10.

PMID:
30655949
4.

The GluN2B-Glu413Gly NMDA receptor variant arising from a de novo GRIN2B mutation promotes ligand-unbinding and domain opening.

Wells G, Yuan H, McDaniel MJ, Kusumoto H, Snyder JP, Liotta DC, Traynelis SF.

Proteins. 2018 Dec;86(12):1265-1276. doi: 10.1002/prot.25595. Epub 2018 Oct 5.

5.

Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer.

Rajitha B, Nagaraju GP, Shaib WL, Alese OB, Snyder JP, Shoji M, Pattnaik S, Alam A, El-Rayes BF.

Mol Carcinog. 2017 Jan;56(1):288-299. doi: 10.1002/mc.22492. Epub 2016 Apr 29.

PMID:
27128654
6.

Inhibition of NF-κB translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer.

Rajitha B, Belalcazar A, Nagaraju GP, Shaib WL, Snyder JP, Shoji M, Pattnaik S, Alam A, El-Rayes BF.

Cancer Lett. 2016 Apr 10;373(2):227-33. doi: 10.1016/j.canlet.2016.01.052. Epub 2016 Feb 2.

PMID:
26850372
7.

Restoration of Microtubule Interaction and Cytotoxicity in D-seco Taxanes upon Incorporation of 20-Hydroxymethyl-4-allyloxy Groups.

Wang SR, Yang CG, Sánchez-Murcia PA, Snyder JP, Yan N, Sáez-Calvo G, Díaz JF, Gago F, Fang WS.

Org Lett. 2015 Dec 18;17(24):6098-101. doi: 10.1021/acs.orglett.5b03119. Epub 2015 Dec 9.

PMID:
26649936
8.

Structural analysis of CXCR4 - Antagonist interactions using saturation-transfer double-difference NMR.

Cox BD, Mehta AK, DiRaddo JO, Liotta DC, Wilson LJ, Snyder JP.

Biochem Biophys Res Commun. 2015 Oct 9;466(1):28-32. doi: 10.1016/j.bbrc.2015.08.084. Epub 2015 Aug 21.

PMID:
26301631
9.

Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells.

Curry E, Green I, Chapman-Rothe N, Shamsaei E, Kandil S, Cherblanc FL, Payne L, Bell E, Ganesh T, Srimongkolpithak N, Caron J, Li F, Uren AG, Snyder JP, Vedadi M, Fuchter MJ, Brown R.

Clin Epigenetics. 2015 Aug 21;7:84. doi: 10.1186/s13148-015-0118-9. eCollection 2015.

10.

Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase.

Cox BD, Prosser AR, Sun Y, Li Z, Lee S, Huang MB, Bond VC, Snyder JP, Krystal M, Wilson LJ, Liotta DC.

ACS Med Chem Lett. 2015 May 6;6(7):753-7. doi: 10.1021/acsmedchemlett.5b00036. eCollection 2015 Jul 9.

11.

Design and Validation of FRESH, a Drug Discovery Paradigm Resting on Robust Chemical Synthesis.

Shi Q, Kaiser TM, Dentmon ZW, Ceruso M, Vullo D, Supuran CT, Snyder JP.

ACS Med Chem Lett. 2015 Apr 3;6(5):518-22. doi: 10.1021/acsmedchemlett.5b00062. eCollection 2015 May 14.

12.

Context-dependent GluN2B-selective inhibitors of NMDA receptor function are neuroprotective with minimal side effects.

Yuan H, Myers SJ, Wells G, Nicholson KL, Swanger SA, Lyuboslavsky P, Tahirovic YA, Menaldino DS, Ganesh T, Wilson LJ, Liotta DC, Snyder JP, Traynelis SF.

Neuron. 2015 Mar 18;85(6):1305-1318. doi: 10.1016/j.neuron.2015.02.008. Epub 2015 Feb 26.

13.

Monocarbonyl analogs of curcumin inhibit growth of antibiotic sensitive and resistant strains of Mycobacterium tuberculosis.

Baldwin PR, Reeves AZ, Powell KR, Napier RJ, Swimm AI, Sun A, Giesler K, Bommarius B, Shinnick TM, Snyder JP, Liotta DC, Kalman D.

Eur J Med Chem. 2015 Mar 6;92:693-9. doi: 10.1016/j.ejmech.2015.01.020. Epub 2015 Jan 10.

14.

Tumor angiogenesis therapy using targeted delivery of Paclitaxel to the vasculature of breast cancer metastases.

Zhu S, Kisiel W, Lu YJ, Petersen LC, Ndungu JM, Moore TW, Parker ET, Sun A, Liotta DC, El-Rayes BF, Brat DJ, Snyder JP, Shoji M.

J Drug Deliv. 2014;2014:865732. doi: 10.1155/2014/865732. Epub 2014 Dec 7.

15.

Eliminating the heart from the curcumin molecule: monocarbonyl curcumin mimics (MACs).

Shetty D, Kim YJ, Shim H, Snyder JP.

Molecules. 2014 Dec 24;20(1):249-92. doi: 10.3390/molecules20010249. Review.

16.

β-1 tubulin R307H SNP alters microtubule dynamics and affects severity of a hereditary thrombocytopenia.

Basciano PA, Matakas J, Pecci A, Civaschi E, Cagioni C, Bompiani N, Burger P, Christos P, Snyder JP, Bussel J, Balduini CL, Giannakakou P, Noris P.

J Thromb Haemost. 2015 Apr;13(4):651-9. doi: 10.1111/jth.12824. Epub 2015 Jan 22.

17.

Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody.

Zhu S, Kisiel W, Lu YJ, Petersen LC, Ndungu JM, Moore TW, Parker ET, Sun A, Sarkaria JN, Snyder JP, Liotta DC, Brat DJ, El-Rayes BF, Shoji M.

J Drug Target. 2015 Apr;23(3):257-65. doi: 10.3109/1061186X.2014.988217. Epub 2014 Dec 16.

18.

Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer.

Nagaraju GP, Zhu S, Ko JE, Ashritha N, Kandimalla R, Snyder JP, Shoji M, El-Rayes BF.

Cancer Lett. 2015 Feb 28;357(2):557-65. doi: 10.1016/j.canlet.2014.12.007. Epub 2014 Dec 9.

PMID:
25497868
19.

Curcumin analog UBS109 prevents bone marrow osteoblastogenesis and osteoclastogenesis disordered by coculture with breast cancer MDA-MB-231 bone metastatic cells in vitro.

Yamaguchi M, Zhu S, Weitzmann MN, Snyder JP, Shoji M.

Mol Cell Biochem. 2015 Mar;401(1-2):1-10. doi: 10.1007/s11010-014-2286-x. Epub 2014 Nov 22.

PMID:
25416449
20.

Approaches to design non-covalent inhibitors for human granzyme B (hGrB).

Kim MS, Buisson LA, Heathcote DA, Hu H, Braddock DC, Barrett AG, Ashton-Rickardt PG, Snyder JP.

Org Biomol Chem. 2014 Nov 28;12(44):8952-65. doi: 10.1039/c4ob01874e.

PMID:
25277547
21.

Autophagy and apoptosis in hepatocellular carcinoma induced by EF25-(GSH)2: a novel curcumin analog.

Zhou T, Ye L, Bai Y, Sun A, Cox B, Liu D, Li Y, Liotta D, Snyder JP, Fu H, Huang B.

PLoS One. 2014 Sep 30;9(9):e107876. doi: 10.1371/journal.pone.0107876. eCollection 2014.

22.

Structural determinants and mechanism of action of a GluN2C-selective NMDA receptor positive allosteric modulator.

Khatri A, Burger PB, Swanger SA, Hansen KB, Zimmerman S, Karakas E, Liotta DC, Furukawa H, Snyder JP, Traynelis SF.

Mol Pharmacol. 2014 Nov;86(5):548-60. doi: 10.1124/mol.114.094516. Epub 2014 Sep 9.

23.

Antiviral atropisomers: conformational energy surfaces by NMR for host-directed myxovirus blockers.

Grimmer C, Moore TW, Padwa A, Prussia A, Wells G, Wu S, Sun A, Snyder JP.

J Chem Inf Model. 2014 Aug 25;54(8):2214-23. doi: 10.1021/ci500204j. Epub 2014 Aug 8.

PMID:
25058809
24.

The quest for a simple bioactive analog of paclitaxel as a potential anticancer agent.

Kingston DG, Snyder JP.

Acc Chem Res. 2014 Aug 19;47(8):2682-91. doi: 10.1021/ar500203h. Epub 2014 Jul 23.

25.

Anti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure.

Cox BD, Prosser AR, Katzman BM, Alcaraz AA, Liotta DC, Wilson LJ, Snyder JP.

Chembiochem. 2014 Jul 21;15(11):1614-20. doi: 10.1002/cbic.201402056. Epub 2014 Jul 2.

26.

Discovery of tetrahydroisoquinoline-based CXCR4 antagonists.

Truax VM, Zhao H, Katzman BM, Prosser AR, Alcaraz AA, Saindane MT, Howard RB, Culver D, Arrendale RF, Gruddanti PR, Evers TJ, Natchus MG, Snyder JP, Liotta DC, Wilson LJ.

ACS Med Chem Lett. 2013 Sep 5;4(11):1025-30. doi: 10.1021/ml400183q. eCollection 2013 Nov 14.

27.

Liver S9 Fraction-Derived Metabolites of Curcumin Analogue UBS109.

Moore TW, Zhu S, Randolph R, Shoji M, Snyder JP.

ACS Med Chem Lett. 2014 Jan 10;5(4):288-92. doi: 10.1021/ml4002453. eCollection 2014 Apr 10.

28.

Group A streptococcus inhibitors by high-throughput virtual screening.

Hu H, Mao S, Bugrysheva JV, Pruett S, Liotta DC, Scott JR, Snyder JP.

Eur J Med Chem. 2014 Jul 23;82:120-6. doi: 10.1016/j.ejmech.2014.05.006. Epub 2014 May 4.

PMID:
24880231
29.

Three rare diseases in one Sib pair: RAI1, PCK1, GRIN2B mutations associated with Smith-Magenis Syndrome, cytosolic PEPCK deficiency and NMDA receptor glutamate insensitivity.

Adams DR, Yuan H, Holyoak T, Arajs KH, Hakimi P, Markello TC, Wolfe LA, Vilboux T, Burton BK, Fajardo KF, Grahame G, Holloman C, Sincan M, Smith AC, Wells GA, Huang Y, Vega H, Snyder JP, Golas GA, Tifft CJ, Boerkoel CF, Hanson RW, Traynelis SF, Kerr DS, Gahl WA.

Mol Genet Metab. 2014 Nov;113(3):161-70. doi: 10.1016/j.ymgme.2014.04.001. Epub 2014 Apr 13.

30.

Mouse pharmacokinetics and metabolism of the curcumin analog, 4-piperidinone,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC 716993).

Reid JM, Buhrow SA, Gilbert JA, Jia L, Shoji M, Snyder JP, Ames MM.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1137-46. doi: 10.1007/s00280-014-2447-3. Epub 2014 Apr 24.

31.

Curcumin analogue UBS109 prevents bone loss in breast cancer bone metastasis mouse model: involvement in osteoblastogenesis and osteoclastogenesis.

Yamaguchi M, Zhu S, Zhang S, Wu D, Moore TM, Snyder JP, Shoji M.

Cell Tissue Res. 2014 Jul;357(1):245-52. doi: 10.1007/s00441-014-1846-4. Epub 2014 Apr 11.

PMID:
24723227
32.

Synthetic curcumin analog UBS109 inhibits the growth of head and neck squamous cell carcinoma xenografts.

Zhu S, Moore TW, Morii N, Howard RB, Culver D, Arrendale RF, Reddy P, Evers TJ, Zhang H, Sica G, Chen ZG, Sun A, Fu H, Khuri FR, Shin DM, Snyder JP, Shoji M.

Curr Cancer Drug Targets. 2014;14(4):380-93.

PMID:
24628271
33.

Regulation of GluA1 α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor function by protein kinase C at serine-818 and threonine-840.

Jenkins MA, Wells G, Bachman J, Snyder JP, Jenkins A, Huganir RL, Oswald RE, Traynelis SF.

Mol Pharmacol. 2014 Apr;85(4):618-29. doi: 10.1124/mol.113.091488. Epub 2014 Jan 22.

34.

Synthesis and Metabolic Studies of Host Directed Inhibitors for Anti Viral Therapy.

Moore TW, Sana K, Yan D, Krumm SA, Thepchatri P, Snyder JP, Marengo J, Arrendale RF, Prussia AJ, Natchus MG, Liotta DC, Plemper RK, Sun A.

ACS Med Chem Lett. 2013 Aug 8;4(8):762-767.

35.

Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer.

Nagaraju GP, Zhu S, Wen J, Farris AB, Adsay VN, Diaz R, Snyder JP, Mamoru S, El-Rayes BF.

Cancer Lett. 2013 Dec 1;341(2):195-203. doi: 10.1016/j.canlet.2013.08.002. Epub 2013 Aug 7.

PMID:
23933177
36.

Structure-activity relationships and pharmacophore model of a noncompetitive pyrazoline containing class of GluN2C/GluN2D selective antagonists.

Acker TM, Khatri A, Vance KM, Slabber C, Bacsa J, Snyder JP, Traynelis SF, Liotta DC.

J Med Chem. 2013 Aug 22;56(16):6434-56. doi: 10.1021/jm400652r. Epub 2013 Aug 2.

37.

Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties.

Brown A, Shi Q, Moore TW, Yoon Y, Prussia A, Maddox C, Liotta DC, Shim H, Snyder JP.

J Med Chem. 2013 May 9;56(9):3456-66. doi: 10.1021/jm4002692. Epub 2013 Apr 23.

38.

Benzenesulfonamides: a unique class of chemokine receptor type 4 inhibitors.

Mooring SR, Liu J, Liang Z, Ahn J, Hong S, Yoon Y, Snyder JP, Shim H.

ChemMedChem. 2013 Apr;8(4):622-32. doi: 10.1002/cmdc.201200582. Epub 2013 Mar 6.

39.

Asymmetric synthesis of host-directed inhibitors of myxoviruses.

Moore TW, Sana K, Yan D, Thepchatri P, Ndungu JM, Saindane MT, Lockwood MA, Natchus MG, Liotta DC, Plemper RK, Snyder JP, Sun A.

Beilstein J Org Chem. 2013;9:197-203. doi: 10.3762/bjoc.9.23. Epub 2013 Jan 30.

40.

Models for predicting IKKA and IKKB blockade.

Hu H, Snyder JP.

J Chem Inf Model. 2012 Dec 21;52(12):3190-9. doi: 10.1021/ci300287t. Epub 2012 Dec 4.

PMID:
23157456
41.

Discovery of a new class of liver receptor homolog-1 (LRH-1) antagonists: virtual screening, synthesis and biological evaluation.

Rey J, Hu H, Kyle F, Lai CF, Buluwela L, Coombes RC, Ortlund EA, Ali S, Snyder JP, Barrett AG.

ChemMedChem. 2012 Nov;7(11):1909-14. doi: 10.1002/cmdc.201200307. Epub 2012 Sep 7.

PMID:
22961990
42.

Binding Model for the Interaction of Anticancer Arylsulfonamides with the p300 Transcription Cofactor.

Shi Q, Yin S, Kaluz S, Ni N, Devi NS, Mun J, Wang D, Damera K, Chen W, Burroughs S, Mooring SR, Goodman MM, Van Meir EG, Wang B, Snyder JP.

ACS Med Chem Lett. 2012 Jun 21;3(8):620-5. doi: 10.1021/ml300042k. eCollection 2012 Aug 9.

43.

Novel curcumin analogue UBS109 potently stimulates osteoblastogenesis and suppresses osteoclastogenesis: involvement in Smad activation and NF-κB inhibition.

Yamaguchi M, Moore TW, Sun A, Snyder JP, Shoji M.

Integr Biol (Camb). 2012 Aug;4(8):905-13. doi: 10.1039/c2ib20045g. Epub 2012 Jul 3.

PMID:
22751853
44.

Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents.

Mun J, Jabbar AA, Devi NS, Yin S, Wang Y, Tan C, Culver D, Snyder JP, Van Meir EG, Goodman MM.

J Med Chem. 2012 Aug 9;55(15):6738-50. doi: 10.1021/jm300752n. Epub 2012 Jul 24.

45.

Ebselen and congeners inhibit NADPH oxidase 2-dependent superoxide generation by interrupting the binding of regulatory subunits.

Smith SM, Min J, Ganesh T, Diebold B, Kawahara T, Zhu Y, McCoy J, Sun A, Snyder JP, Fu H, Du Y, Lewis I, Lambeth JD.

Chem Biol. 2012 Jun 22;19(6):752-63. doi: 10.1016/j.chembiol.2012.04.015.

46.

Mapping the binding of GluN2B-selective N-methyl-D-aspartate receptor negative allosteric modulators.

Burger PB, Yuan H, Karakas E, Geballe M, Furukawa H, Liotta DC, Snyder JP, Traynelis SF.

Mol Pharmacol. 2012 Aug;82(2):344-59. doi: 10.1124/mol.112.078568. Epub 2012 May 17.

47.

Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts.

Zhu S, Moore TW, Lin X, Morii N, Mancini A, Howard RB, Culver D, Arrendale RF, Reddy P, Evers TJ, Zhang H, Sica G, Chen ZG, Sun A, Fu H, Khuri FR, Shin DM, Snyder JP, Shoji M.

Integr Biol (Camb). 2012 Jun;4(6):633-40. doi: 10.1039/c2ib20007d. Epub 2012 Apr 25.

48.

Development of a unique small molecule modulator of CXCR4.

Liang Z, Zhan W, Zhu A, Yoon Y, Lin S, Sasaki M, Klapproth JM, Yang H, Grossniklaus HE, Xu J, Rojas M, Voll RJ, Goodman MM, Arrendale RF, Liu J, Yun CC, Snyder JP, Liotta DC, Shim H.

PLoS One. 2012;7(4):e34038. doi: 10.1371/journal.pone.0034038. Epub 2012 Apr 2.

49.

Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase: synthesis, structure-activity relationships, and pharmacokinetics.

Ndungu JM, Krumm SA, Yan D, Arrendale RF, Reddy GP, Evers T, Howard R, Natchus MG, Saindane MT, Liotta DC, Plemper RK, Snyder JP, Sun A.

J Med Chem. 2012 May 10;55(9):4220-30. doi: 10.1021/jm201699w. Epub 2012 Apr 20.

50.

Host-directed Inhibitors of Myxoviruses: Synthesis and in vitro Biochemical Evaluation.

Sun A, Ndungu JM, Krumm SA, Yoon JJ, Thepchatri P, Natchus M, Plemper RK, Snyder JP.

ACS Med Chem Lett. 2011 Aug 23;2(11):798-803.

Supplemental Content

Loading ...
Support Center